SBI Securities’s Enanta Pharmaceuticals ENTA Stock Holding History

SBI Securities’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$16	–	4066
2025 Q4	$16	Hold	1	–	–	﹤0.01%	3810
2025 Q3	$12	Buy	+1	New	+$8	﹤0.01%	4005

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SBI Securities's ENTA Position: Q1 2026 in Review

SBI Securities sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 1 share — an estimated $16 sold.

SBI Securities first reported a position in ENTA in Q3 2025 and held it in 2 quarters. The position peaked at $16 in Q4 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

SBI Securities reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
SBI Securities sold 1 Enanta Pharmaceuticals share in Q1 2026, an estimated $16.
SBI Securities first reported a position in Enanta Pharmaceuticals in Q3 2025 and held it in 2 quarters.
SBI Securities's Enanta Pharmaceuticals position peaked at $16 in Q4 2025.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.